Key result
High pre-procedural fibrinogen linked to ~470% higher risk of major events post-PCI.
Why the study?
The role of fibrinogen in adverse outcomes after coronary stent implantation is controversial, prompting this study to determine the impact and relation of periprocedural fibrinogen levels on post-stenting outcomes.
Does high periprocedural plasma fibrinogen level predict adverse outcomes in patients with chronic stable angina undergoing elective PCI?
Population
53 patients with chronic stable angina undergoing elective PTCA followed by stenting
Comparison
Patients grouped by favorable outcome vs unfavorable or adverse outcome, or high vs lower fibrinogen
Design
Prospective study
Follow-up
6 months
Authors
Loading...
May aid risk stratification in elective PCI; leaves open whether fibrinogen is a modifiable target in stable angina.
Observational (n=53)
No
Does high periprocedural plasma fibrinogen level predict adverse outcomes in patients with chronic stable angina undergoing elective PCI?
Effect estimate: RR 5.7 (95% CI 1.1-30.2)
Absolute Event Rate: 27.2% vs 4.8%
p-value: p=0.023
High periprocedural plasma fibrinogen levels (≥350 mg/dl) are strongly associated with an increased risk of adverse clinical outcomes following elective PCI in patients with chronic stable angina.
Samsuzzaman et al. (2021) conducted an observational in Chronic stable angina undergoing elective PTCA followed by stenting (n=53). High serum fibrinogen (≥350 mg/dl) pre-PCI vs. Low serum fibrinogen (<350 mg/dl) pre-PCI was evaluated on Unfavorable outcome (unstable angina, myocardial infarction, repeat revascularization, or death) (RR 5.7, 95% CI 1.1-30.2, p=0.023). High pre-procedural serum fibrinogen levels (≥350 mg/dl) increased the risk of unfavorable clinical outcomes following percutaneous coronary intervention by 5.7 times compared to lower levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: